Serum gamma glutamyl transferase and alanine transaminase concentrations predict endothelial dysfunction in patients with non-alcoholic steatohepatitis

Upsala Journal of Medical Sciences

Volumn 118, Issue 4, 2013, Pages 228-234

  Arinc, Huseyin ^a   Sarli, Bahadir ^a   Baktir, Ahmet Oguz ^a   Saglam, Hayrettin ^a   Demirci, Erkan ^a   Dogan, Yasemin ^a   Kurtul, Serkan ^a   Karaman, Hatice ^b   Erden, Abdulsamet ^b   Karaman, Ahmet ^b  

^a KAYSERI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b Kayseri Education and Research Hospital ^*  (Turkey)

Author keywords

Alanine transaminase; Endothelial dysfunction; Gamma glutamyl transferase; Non alcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; INSULIN; OXYGEN; TRIACYLGLYCEROL;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BIOPSY; BLOOD; CAROTID ARTERY; CASE CONTROL STUDY; CHEMISTRY; DOPPLER FLOWMETRY; ECHOGRAPHY; ENZYMOLOGY; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; LIVER; MALE; METABOLISM; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PATHOLOGY; PREDICTIVE VALUE; REGRESSION ANALYSIS; VASCULAR ENDOTHELIUM;

ADULT; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; BIOPSY; BLOOD GLUCOSE; CAROTID ARTERIES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CHOLESTEROL; ENDOTHELIUM, VASCULAR; FATTY LIVER; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; INFLAMMATION; INSULIN; LIVER; MALE; MIDDLE AGED; OXYGEN; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; TRIGLYCERIDES; ULTRASONOGRAPHY, DOPPLER;

EID: 84885439944     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009734.2013.814734     Document Type: Article

References (38)

1. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008;134:1682-98.
2. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med. 2005;22:1129-33.
3. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenter-ology. 1999;116:1413-19.
4. Kostapanos MS, Athyros VG, Karagiannis A, Mikhailidis DP. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci. 2012;57:1109.
5. Brea A, Mosquera D, Martín E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol. 2005;25:1045-50.
6. Assy N, Djibre A, Farah R, Grosovski M, Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology. 2010;254:393-400.
7. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899-906.
8. Takase B, Uehata A, Akima T, Nagai T, Nishioka T, Hamabe A, et al. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol. 1998;82:1535-9.
9. Pascale A, Pais R, Ratziu V. An overview of nonalcoholic steatohepatitis: past, present and future directions. J Gastrointestin Liver Dis. 2010;19:415-23.
10. Brunt EM. Pathology of nonalcoholic steatohepatitis. Hepatol Res. 2005;33:68-71.
11. Franzini M, Fornaciari I, Fierabracci V, Elawadi HA, Bolognesi V, Maltinti S, et al. Accuracy of b-GGT fraction for the diagnosis of non-alcoholic fatty liver disease. Liver Int. 2012;32:629-34.
12. Fletcher LM, Kwoh-Gain I, Powell EE, Powell LW, Halliday JW. Markers of chronic alcohol ingestion in patients with nonalcoholic steatohepatitis: an aid to diagnosis. Hepa-tology. 1991;13:455-9.
13. Banderas DZ, Escobedo J, Gonzalez E, Liceaga MG, Ramírez JC, Castro MG. g-Glutamyl transferase: a marker of nonalcoholic fatty liver disease in patients with the metabolic syndrome. Eur J Gastroenterol Hepatol. 2012;24:805-10.
14. Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis. 2007;191:391-6.
15. Westerbacka J, Cornér A, Tiikkainen M, Tamminen M, Vehkavaara S, Häkkinen AM, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia. 2004;47:1360-9.
16. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121:91-100.
17. Yagmur J, Ermis N, Acikgoz N, Cansel M, Atas H, Karakus Y, et al. Elevated serum gamma-glutamyl transferase activity in patients with cardiac syndrome X and its relationship with carotid intima media thickness. Acta Cardiol. 2010; 65:515-19.
18. Aksakal E, Tanboga IH, Kurt M, Kaygin MA, Kaya A, Isik T, et al. The relation of serum gamma-glutamyl trans-ferase levels with coronary lesion complexity and long-term outcome in patients with stable coronary artery disease. Atherosclerosis. 2012;221:596-601.
19. Dogan A, Icli A, Aksoy F, Varol E, Erdogan D, Ozaydin M, et al. Gamma-glutamyltransferase in acute coronary syndrome patients without ST elevation and its association with stenotic lesion and cardiac events. Coron Artery Dis. 2012;23:39-44.
20. Akpek M, Elcik D, Kalay N, Yarlioglues M, Dogdu O, Sahin O, et al. The prognostic value of serum gamma glutamyl transferase activity on admission in patients with STEMI undergoing primary PCI. Angiology. 2012;63:579-85.
21. Schindhelm RK, Diamant M, Bakker SJ, van Dijk RA, Scheffer PG, Teerlink T, et al. Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotrigly-ceridaemic subjects with type 2 diabetes mellitus. Eur J Clin Invest. 2005;35:369-74.
22. Stoner L, Erickson ML, Young JM, Fryer S, Sabatier MJ, Faulkner J, et al. There's more to flow-mediated dilation than nitric oxide. J Atheroscler Thromb. 2012;19:589-600.
23. Charakida M, Masi S, Lüscher TF, Kastelein JJ, Deanfield JE. Assessment of atherosclerosis: the role of flow-mediated dilatation. Eur Heart J. 2010;31:2854-61.
24. Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51:595-602.
25. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005;42:473-80.
26. Fracanzani AL, Burdick L, Raselli S, Pedotti P, Grigore L, Santorelli G, et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med. 2008;121:72-8.
27. Turgut O, Yilmaz A, Yalta K, Karadas F, Yilmaz MB. Gamma glutamyl transferase is a promising biomarker for cardiovascular risk. Med Hypotheses. 2006;67:1060-4.
28. Lee DH, Gross MD, Jacobs DR. Jr; Cardiovascular Risk Development in Young Adults Study. The association of serum carotenoids and tocopherols with gamma glutamyl-transferase the CARDIA study. Clin Chem. 2004;50:582-8.
29. Lee DH, Blomhoff R, Jacobs DR. Is serum gamma glutamyl-transferase a marker of oxidative stress? Free Radic Res. 2004; 38:535-9.
30. Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;27:127-33.
31. Demirkan B, Güray Y, Güray Ü, Turak O, Hajro E, Korkmaz S. The relationship between saphenous coronary bypass graft occlusion and serum gamma-glutamyltransferase activity. Turk Kardiyol Dern Ars. 2010;38:321-6.
32. Nseir W, Shalata A, Marmor A, Assy N. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci. 2011;56:3439-49.
33. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002;50:585-8.
34. Unger RH. Lipotoxic diseases. Annu Rev Med. 2002;53:319-36.
35. Kerner A, Avizohar O, Sella R, Bartha P, Zinder O, Markiewicz W, et al. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arter-ioscler Thromb Vasc Biol. 2005;25:193-7.
36. Turgut O, Tandogan I. Gamma-glutamyltransferase to determine cardiovascular risk: shifting the paradigm forward. J Atheroscler Thromb. 2011;18:177-81.
37. Lee DH, Jacobs DR Jr. Association between serum gamma-glutamyltransferase and C-reactive protein. Atherosclerosis. 2005;178:327-30.
38. Lee DH, Jacobs DR, Gross M, Kiefe CI, Roseman J, Lewis CE, et al. Gamma glutamyltransferase is a predictor of incident diabetes and hypertension: the CARDIA Study. Clin Chem. 2003;49:1358-66.